Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Sodium citrate + ethanol** is a sterile, single-use catheter-lock solution containing 4% sodium citrate and 30% ethanol, marketed as **CitraFlow PLUS** and regionally as **CitraLok PLUS**. It is instilled into the lumen of an indwelling vascular-access or hemodialysis catheter between treatments rather than administered as a systemic infusion. Citrate chelates ionized calcium to inhibit calcium-dependent coagulation within the catheter, helping maintain patency and prevent thrombosis, while ethanol provides broad local antimicrobial activity and may reduce intraluminal biofilm formation. A University of Manitoba randomized pilot study evaluated the 30% ethanol/4% sodium citrate lock versus heparin for prevention of catheter-related infection, bacteremia, and thrombosis in patients with stage V chronic kidney disease receiving hemodialysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium citrate + ethanol.